On September 17, 2026, the Massachusetts Appeals Court affirmed a judgment for a patient who developed Stevens-Johnson syndrome (SJS) after being prescribed Lamictal (lamotrigine) as a 13-year-old. The case is important not because it creates a new pharmaceutical warning rule, but because it illustrates several recurring issues in serious SJS cases: dosing and titration, individualized prescribing, permanent ocular and mucosal injury, medical-causation evidence, and the distinction between a medical-negligence claim and a product-liability claim.
According to the appellate decision, the patient weighed approximately 60 pounds. She was prescribed Lamictal at 25 mg every other day. The defense contended that this dosage followed the FDA age-based guidance applicable to patients age 12 and older. The plaintiff's expert, however, testified that the patient's unusually small size required a substantially lower initial dose and that the prescribed dose did not meet the standard of care in her particular circumstances.
The injuries show why long-term SJS damages must be documented
The appellate court's account describes a devastating course. The patient's eyes swelled shut; painful blisters and lesions affected her hands, mouth, face, and body; she required tube feeding; and she needed round-the-clock monitoring for months after discharge. Years later, the record reflected scarring, permanent visual impairment, and severe genitourinary complications.
Those details matter beyond this particular case. SJS and toxic epidermal necrolysis (TEN) can produce permanent injuries long after the acute hospitalization ends. A thorough legal evaluation should therefore obtain not only the burn-unit or initial hospital records, but also long-term ophthalmology and cornea records, gynecology or urology records when mucosal injury is involved, dermatology records, photographs, rehabilitation records, and evidence of future medical needs.
What the appeal actually decided
The appellate ruling should not be overstated. The principal issue on appeal was not whether Lamictal can cause SJS; the case proceeded on the premise that the medication caused the patient's reaction. Nor did the Appeals Court announce a general rule that FDA dosing guidance is inadequate.
Instead, the defendants challenged the trial judge's decision to give a missing-witness instruction after the defense did not call the attending physician whom it had portrayed as the final decisionmaker on the prescription. The Appeals Court concluded that the trial judge did not abuse her discretion and affirmed the judgment.
The underlying jury verdict nevertheless remains instructive. The jury accepted the plaintiff's negligence theory despite the defense argument that the prescribed dose complied with age-based FDA guidance. That demonstrates why compliance with labeling or generalized dosing instructions may not resolve a medical-negligence inquiry when patient-specific facts are alleged to require different clinical judgment.
Lamotrigine already carries a prominent serious-rash warning
Lamotrigine is a well-recognized SJS/TEN-associated medication. Current U.S. labeling contains a boxed warning for serious skin rashes, including SJS and TEN, and identifies factors that may increase rash risk, including exceeding recommended initial dosing or dose escalation and certain concomitant therapy.
That warning history is legally significant, but it cuts in more than one direction. In a medical-negligence case, the questions may include whether the drug was prescribed and titrated appropriately, whether early rash or systemic symptoms were recognized, and whether the medication was discontinued promptly. In a pharmaceutical product-liability case, separate questions arise about the exact manufacturer, the label in effect at the time, the adequacy of the warning, and federal preemption - particularly when a generic lamotrigine product was dispensed.
Brand versus generic exposure remains critical
Patients often remember the name Lamictal even when the pharmacy actually dispensed generic lamotrigine. That distinction can be decisive. Federal law can substantially restrict traditional failure-to-warn claims against generic manufacturers because generic labeling generally must match the reference-listed drug labeling.
For that reason, the pharmacy dispensing history, National Drug Code (NDC), prescription bottle or packaging, manufacturer identity, and dates of each fill should be preserved as early as possible. A strong medical-causation case does not automatically mean there is a viable product-liability defendant.
California and statute-of-limitations considerations
The Massachusetts decision does not control California courts, but its factual lessons are relevant nationally. California SJS/TEN cases require their own analysis of medical negligence, product liability, prescribing and dispensing history, manufacturer identity, warning chronology, causation, and applicable statutes of limitation.
Timing is especially important. Different claims may accrue under different rules, and waiting for every long-term complication to become clear can jeopardize a claim. Families dealing with SJS/TEN should preserve medication and pharmacy records promptly and obtain case-specific advice about the deadlines that apply in the relevant jurisdiction.
What this decision means for evaluating an SJS/TEN case
The decision reinforces a practical point: serious SJS litigation cannot be evaluated from the drug name alone. Counsel should reconstruct the exact dose, titration schedule, patient age and weight, concomitant medications, date of first exposure, onset of symptoms, date of discontinuation, prescriber communications, manufacturer identity, and the full course of acute and chronic injury.
For lamotrigine cases in particular, the dosing and titration record deserves careful scrutiny. The existence of a known SJS warning does not eliminate potential medical-negligence issues, just as a severe reaction does not by itself establish negligence or product liability. Each theory requires its own factual, scientific, and legal analysis.
Sources
Massachusetts Lawyers Weekly report on the underlying $8 million verdict, Feb. 7, 2025
Keches Law Group report on appellate affirmance, Oct. 1, 2026
FDA/DailyMed lamotrigine labeling - serious skin rash/SJS/TEN warning